KRAS and cancer: Therefore, XPO1inhibition has emerged as an appealing anticancer strategy [9], especially in view of multiple reports implicating XPO1 to be a generalvulnerability across several types of cancer [12].Interestingly, it has been reported that KRAS-mutant cancer cells are dependent on XPO1mediated nuclear export, rendering XPO1 a druggable vulnerability in KRAS-mutant cancer[13].